Wishart Gabrielle, Templeman Amy, Hendry Francesca, Miller Karen, Pailhes-Jimenez Anne-Sophie
ANGLE plc, Guildford GU2 7QB, UK.
Curr Issues Mol Biol. 2024 Jan 17;46(1):773-787. doi: 10.3390/cimb46010050.
The study of molecular drivers of cancer is an area of rapid growth and has led to the development of targeted treatments, significantly improving patient outcomes in many cancer types. The identification of actionable mutations informing targeted treatment strategies are now considered essential to the management of cancer. Traditionally, this information has been obtained through biomarker assessment of a tissue biopsy which is costly and can be associated with clinical complications and adverse events. In the last decade, blood-based liquid biopsy has emerged as a minimally invasive, fast, and cost-effective alternative, which is better suited to the requirement for longitudinal monitoring. Liquid biopsies allow for the concurrent study of multiple analytes, such as circulating tumour cells (CTCs) and circulating tumour DNA (ctDNA), from a single blood sample. Although ctDNA assays are commercially more advanced, there is an increasing awareness of the clinical significance of the transcriptome and proteome which can be analysed using CTCs. Herein, we review the literature in which the microfluidic, label-free Parsortix system is utilised for CTC capture, harvest and analysis, alongside the analysis of ctDNA from a single blood sample. This detailed summary of the literature demonstrates how these two analytes can provide complementary disease information.
癌症分子驱动因素的研究是一个快速发展的领域，并已促成了靶向治疗的发展，显著改善了许多癌症类型患者的治疗结果。确定可指导靶向治疗策略的可操作突变现在被认为是癌症管理的关键。传统上，这些信息是通过组织活检的生物标志物评估获得的，这成本高昂，并且可能与临床并发症和不良事件相关。在过去十年中，基于血液的液体活检已成为一种微创、快速且经济高效的替代方法，更适合纵向监测的需求。液体活检允许从单个血液样本中同时研究多种分析物，例如循环肿瘤细胞（CTC）和循环肿瘤DNA（ctDNA）。尽管ctDNA检测在商业上更为先进，但人们越来越意识到可以使用CTC分析的转录组和蛋白质组的临床意义。在此，我们回顾了利用微流控、无标记的Parsortix系统进行CTC捕获、收获和分析以及从单个血液样本中分析ctDNA的文献。对文献的这一详细总结展示了这两种分析物如何能够提供互补的疾病信息。
